Articles tagged "Hepatitis C"

2016 American Transplant Congress
Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.
S. Helmke,¹ J. O'Leary,² J. Burton,¹ M. Cookson,¹ S. Lauriski,¹ J. Trotter,² J. McHutchison,³ G. Everson.¹
¹University of Colorado, Aurora, CO; ²Baylor University Medical Center, Dallas, TX; ³Gilead Sciences, Inc., Foster City, CA.
Background: In SOLAR-1, liver transplant recipients with HCV and either fibrosis or cirrhosis were treated at baseline with ledipasvir/sofosbuvir and ribavirin for 12 or 24…
2016 American Transplant Congress
Hepatitis C Eradication with Sofosbuvir Based Regimens Leads to Significant Metabolic Changes in Post Orthotopic Liver Transplant Patients.
A. Morales,¹ M. Singla,² H. Greenwald,¹ S. Robertazzi,¹ C. Rodigas,¹ V. Washington,¹ R. Satoskar,¹ C. Smith.¹
¹MedStar Transplant Institute, Georgetown University Hospital, Washington, DC; ²Gastroenterology Service, Walter Reed National Military Medical Center, Bethesda, MD.
The purpose of this study was to assess the effect of hepatitis C virus (HCV) eradication with sofosbuvir based regimens on glycemic and lipid control…
2016 American Transplant Congress
Decline of HCV RNA and Core Antigen: Predictors of Achieving SVR in Transplant Recipients Undergoing DAA-Therapy.
S. Pischke,³ V. Proske,¹ S. Polywka,⁴ M. Lütgehetmann,⁴ M. Lang,¹ S. Stauga,¹ L. Fischer,¹ A. Lohse,³ B. Nashan,² M. Sterneck.¹
¹University Transplant Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; ²Department of Hepatobiliary Surgery and Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany; ³Department of Medicine, University Hospital Hamburg Eppendorf, Hamburg, Greece; ⁴Department of Microbiology, University Hospital Hamburg Eppendorf, Hamburg, Germany.
Background:DAA-treatment of hepatitis C virus (HCV) re-infections in orthotopic liver transplant (OLT) recipients has been demonstrated to be safe and effective in controlled studies, but…
2016 American Transplant Congress
Virological Response at 4 Weeks With a Sofosbuvir-Based Antiviral Regimen in Liver Transplant Recipients with Recurrent Hepatitis C.
T. Pastrana-Camacho,¹ M. Bradley,¹ H. Winters,¹ S. Black,² K. Porter,³ K. Mumtaz.⁴
¹Pharmacy, The Ohio State University-Wexner Medical Center, Columbus, OH; ²Department of Surgery, The Ohio State University-Wexner Medical Center, Columbus, OH; ³Center for Biostatistics, The Ohio State University-Wexner Medical Center, Columbus, OH; ⁴Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, The Ohio State University-Wexner Medical Center, Columbus, OH.
Background: The literature is growing in the area of safety, efficacy and tolerability of sofosbuvir (SOF)- based antivirals therapy (AVT) in recurrent hepatitis C virus…
2016 American Transplant Congress
Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.
J. Wedd, R. Ford, J. Norvell, S. Parekh, N. Cheng, N. Young, A. Patel, R. Maheshwari, R. Vora, O. Mgbemena, J. Spivey, A. Pillai.
Medicine, Emory University, Atlanta, GA.
Background/Aims: Controlled trials of direct acting antiviral therapy for Hepatitis C Virus (HCV) show impressive sustained virologic response (SVR) rates, but post-transplant data of sofosbuvir…
2016 American Transplant Congress
Sofosbuvir-Based Regimen in Treatment Experienced-Post Liver Transplant Patients with Hepatitis C Recurrence.
A. Ajlan,¹ A. Aljedai,¹ H. Elsiesy,² D. Alkortas,¹ R. Alarieh,² W. Alhumodi,² D. Broring,² M. Alsebayel,² F. Aba Alkhail.²
¹Pharmaceutical Care, KFSHRC, Riyadh, Saudi Arabia; ²Liver and Small Bowel Transplant, KFSHRC, Riaydh, Saudi Arabia.
This is an open label, prospective, interventional cohort study conducted at a tertiary referral center. The primary end point is SVR12 in patients treated with…
2016 American Transplant Congress
Successful Treatment of Hepatitis C in Renal Transplant Recipients with Directly Acting Antiviral Agents.
M. Lubetzky,¹ S. Chun,¹ A. Joelson,¹ E. Akalin,¹ P. Gaglio,² G. DeBoccardo.¹
¹Transplantation, Albert Einstein College of Medicine, Bronx, NY; ²Hepatology, Columbia Universtiy, New York, NY.
Background: Hepatitis C infection (HCV) in kidney transplant (KTx) recipients has been shown to be a risk factor for decreased patient and allograft survival. With…
2016 American Transplant Congress
Initial Experience with Ledipasvir-Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation.
A. Weick, O. Sadiq, S.-M. Jafri, D. Moonka.
Henry Ford Hospital, Detroit, MI.
Objectives:Evaluate outcomes of Ledipasvir-Sofosbuvir based hepatitis C therapy in liver transplant patients at a single center.Methods:All post-liver transplant patients started on Ledipasvir-Sofosbuvir therapy between January…
2016 American Transplant Congress
Hepatitis C Patients in a Multicenter Study Who Received Living Donor Liver Transplants Are Likely to Have Increased Survival.
J. Kim,¹ K.-W. Lee,² G.-W. Song,³ B.-H. Jung,³ H. Lee,⁴ N.-J. Yi,² C. Kwon,¹ S. Hwang,³ K.-S. Suh,² J.-W. Joh,¹ S.-K. Lee,¹ S.-G. Lee.³
¹Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; ²Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; ³Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; ⁴Department of Surgery, Seoul National University Boramae Medical Center, Seoul, Korea.
Background: No consensus has been reached regarding comparisons of outcomes for patients with hepatitis C virus (HCV) who received living donor liver transplantation (LDLT) versus…
2016 American Transplant Congress
Safety and Efficacy of Ledipasvir/Sofosbuvir (LS) with or without Ribavirin (RBV) for Treatment of Recurrent Hepatitis C Infection Post-Liver Transplant.
K. Gutierrez, J. Scheuermann, I. Goldvarg, S. Joshi, G. Tyson, N. Bzowej, N. Girgrah, S. Anders, G. Loss, G. Therapondos.
Mulit-Organ Transplant Institute, Ochsner Medical Center, New Orleans, LA.
Background: Hepatitis C (HCV) is the most common indication for liver transplant in the United States representing more than 40% of all recipients. Availability of…